In conclusion, probiotic VSL#3 is anticipated to be a first-choice medication in managing colitis because it reduces the production of NF-κB and TNF-α in rats with colitis via the TLR4-NF-κB signal pathway. The gene discussed is TLR4; the disease is colitis.